We now offer Private Weight Loss Treatments

Retatrutide Research Explained: What the New NEJM Study Means

Magnifying glass over layered laboratory reports illustrating careful interpretation of blood test results.
NEWS · 7 minute read
Rahul Puri
Written by Rahul PuriPharmacist, MPharm
Medically reviewed 3 November 2026
Share:
Stay informed

Get practical health advice and updates on Puri Pharmacy services straight to your inbox.

New obesity research often makes headlines for its weight-loss percentage. For patients, the more useful questions are what was studied, what the results mean for health and whether the findings should change their care today.

A study published in the New England Journal of Medicine on 29 September 2026 investigated retatrutide in adults without diabetes. It examined weight reduction and outcomes in participants with knee osteoarthritis or obstructive sleep apnoea. [1]

Retatrutide remains investigational. This article explains research; it is not an offer of treatment or a recommendation to use retatrutide. Lilly describes it as an investigational molecule that cannot legally be sold or marketed for human use. [2]

Illustration of weighing clinical evidence
Assess potential benefits, limitations and follow-up together.

What is retatrutide?

Retatrutide is being developed by Eli Lilly. It acts on three hormone receptors: GIP, GLP-1 and glucagon. Researchers are investigating whether this combination can help treat obesity and related conditions. [2]

A different mechanism does not automatically establish that a treatment is better or safer than existing options. That requires appropriate comparative evidence, safety assessment and regulatory decisions.

What did the new study find?

TRIUMPH-1 was a phase 3, randomised, double-blind trial involving 2,339 participants. Retatrutide was compared with placebo over 80 weeks. The published abstract reports the following average weight changes using the treatment-regimen analysis, which accounts for treatment discontinuation and other specified events. [1]

Study groupAverage body-weight change at 80 weeks
Retatrutide 4 mg−17.6%
Retatrutide 9 mg−23.7%
Retatrutide 12 mg−25.0%
Placebo−3.9%

These are research results in trial groups, not predictions for an individual patient or suggested doses.

The study also reported improvements versus placebo in knee pain among participants with knee osteoarthritis and in breathing-event frequency among participants with obstructive sleep apnoea. Gastrointestinal adverse events were the most common. Eli Lilly funded the trial. [1]

Why the health outcomes deserve attention

The clinical question extends beyond a change in weight. For someone living with obesity, health priorities may include being able to move more comfortably, manage another condition or take part in everyday activities.

The NHS identifies joint pain and sleep apnoea among health problems that may accompany overweight and obesity. [3] Considering these conditions helps frame weight management around health needs rather than appearance alone.

Our interpretation is that research assessing symptoms and related conditions offers a more useful picture than a headline about kilograms lost. It helps clinicians ask what benefit matters to the patient. It does not mean that a single trial answers every question about long-term health.

What the study does not tell you

It does not establish superiority over existing treatments

The comparator was placebo. A direct comparison with another active treatment would be needed to establish comparative effectiveness under the same study conditions.

Putting percentages from separate studies next to each other can be misleading. Participant characteristics, follow-up periods and statistical methods may differ. A larger headline number is not enough to decide which treatment is suitable for a particular person.

It does not promise the same result for every patient

An average summarises a group. It cannot tell you precisely how one person will respond or whether they will tolerate treatment.

It does not make an investigational medicine available through a pharmacy

Publication in a respected journal is a step in evidence development. It is different from regulatory authorisation, an approved prescribing indication or routine availability.

Do not treat an online product listing or a social-media claim as evidence of any of those things.

It does not remove the need to assess risks

Benefits and adverse effects need to be considered together. Before any new treatment enters routine care, clinicians and regulators need sufficient evidence about suitability, safety and appropriate use. An impressive result cannot substitute for that assessment.

What if you have sleep apnoea or knee pain?

Continue the care plan agreed with your healthcare professionals. Research headlines are not a reason to stop or alter existing treatment.

The NHS explains that sleep-apnoea care may involve lifestyle changes and a CPAP machine, which supplies air through a mask during sleep. [4] Do not stop CPAP because you have lost weight or read about a new medicine. Discuss reassessment with your sleep service.

Persistent knee pain also deserves assessment on its own terms. A weight-management conversation can sit alongside appropriate care for symptoms; it should not replace it.

Why ongoing clinical support still matters

Research may change the options available in future. Patients still need help understanding what is suitable now, what to expect and when their plan needs review.

NICE recommends regular review to monitor the effects of weight-management medicines and reinforce behavioural advice and adherence. It also recommends support when people stop these medicines. [5]

Our view at Puri Pharmacy is that the same practical questions remain central to care:

  • What are your individual health goals?
  • Is the agreed plan suitable and manageable?
  • Are changes in symptoms or circumstances being discussed?
  • Do you understand when and how to obtain clinical advice?
  • Does your longer-term plan need reassessment?

Digital check-ins and educational resources can help patients prepare for these conversations. They do not replace clinical judgement. This study did not test Puri Pharmacy’s service, Aide Health or the effectiveness of our wraparound-care approach.

What should patients do with this information?

Use research to ask informed questions, rather than to choose a treatment based on a headline.

If you are already receiving weight-management care, discuss concerns or proposed changes with your prescriber. If you are considering care for the first time, focus on an individual assessment, realistic expectations and clear information about follow-up.

For readers in Southall, Hillingdon and surrounding West London areas, face-to-face discussion may be useful. Wherever you receive care, ask how your provider assesses suitability, monitors progress and responds when your needs change.

Frequently asked questions

Can I obtain retatrutide from Puri Pharmacy?

This article is a research update, not a retatrutide service page. Retatrutide remains investigational as of 1 October 2026. It should not be treated as an available routine pharmacy treatment. [2]

Is retatrutide proven to be better than other weight-loss medicines?

This placebo-controlled trial does not establish that. Comparisons require appropriate evidence rather than headline figures from different studies.

Does an average 25% reduction mean I would lose 25%?

No. A trial average does not predict an individual outcome.

Does the study show that sleep apnoea or osteoarthritis is cured?

Improvement in an outcome measure should not be described as a guaranteed cure. Existing assessment and condition-specific care remain important.

Should I change my current treatment because of this paper?

Do not change treatment based on this article. Discuss your current health, goals and concerns with the healthcare professional responsible for your care.

Illustration of safety and source checking
Promising trial findings and unanswered safety questions both belong in the discussion.
Rahul Puri, pharmacist

Ask Rahul

Rahul Puri | Pharmacist

Peptide evidence, safety and UK regulation

Can I be encouraged by the result without changing my treatment?

Yes. Acknowledge what the trial found while asking what it did not test. The placebo comparison supports a research finding; it does not rank every available treatment or predict your own outcome. Discuss any proposed change with your prescriber.

References

  1. Jastreboff AM and colleagues. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. Published 29 September 2026. DOI 10.1056/NEJMoa2604169.
  2. Eli Lilly — Retatrutide research update, 29 September 2026. Used for current investigational status and mechanism; TRIUMPH-2 figures from this separate announcement are not used as TRIUMPH-1 results.
  3. NHS — Overweight and obesity in adults.
  4. NHS — Sleep apnoea.
  5. NICE NG246 — Medicines and surgery.
Share:
Stay informed

Get practical health advice and updates on Puri Pharmacy services straight to your inbox.